Tyme Technologies (Tyme Technologies) Momentum Rank : 5 (As of May. 06, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Momentum Rank?

Tyme Technologies has the Momentum Rank of 5.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Tyme Technologies's Momentum Rank

For the Biotechnology subindustry, Tyme Technologies's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyme Technologies's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's Momentum Rank falls into.

Tyme Technologies Momentum Rank Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105